Patients suffering from life-threatening allergies always carry a life-saving companion with them: an adrenaline autoinjector in order to immediately inject themselves in the event of an anaphylactic shock and to thus counter an allergic reaction. For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an Autoinjector-Label with special protection against abrasion. Thus, the vital user and product information remains perfectly legible over an extended period of time. The label won an award in the 2019 TLMI Competition. Epinephrine is a prescription drug for the treatment of life-threatening allergic emergencies. TEVA, a worldwide leader in generic drugs and specialty medicines, offers the adrenaline in single-dose, prefilled disposable autoinjectors. The label developed by Schreiner MediPharm for this injector is provided with abrasion- and scratch-resistant reverse printing. As a result, it is particularly resistant against chemical and mechanical impacts it is exposed to while the autoinjector is being carried in a purse or backpack, for instance. Due to its special material construction and design that is precisely adapted to the sophisticated shape of the autoinjector, the marking label securely adheres to the device. Thus, the vital information about the product and its use is reliably legible and readily available at all times. An additional cover protecting the label against abrasion or separation is not necessary, which reduces waste and the environmental footprint. For product and patient safety, the label features a perforation that clearly and irreversibly indicates any first opening of the cap and thus any potential tampering attempt. The TEVA Autoinjector-Label won recognition in the yearly North American Tag and Label Manufacturers Institute (TLMI) Competition that awarded Schreiner MediPharm’s product development with second place in the “Multi-Process” category in 2019. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com For additional information, contact: Schreiner MediPharm, a business unit of Schreiner Group GmbH & Co. KG Bruckmannring 22 85764 Oberschleissheim Germany Phone +49 89 31584-5400 Fax +49 89 31584-5422 info@schreiner-medipharm.com www.schreiner-medipharm.com

The motor is the centerpiece of an e-bike. The belt drive from Brose Antriebstechnik features an extremely quiet, robust and low-maintenance design and makes for a feeling of natural riding. The belt is installed in a protective housing. For reliable proof of the most recent maintenance, Schreiner ProTech developed a tamper-evident label with first-opening indication for Brose Antriebstechnik modified to suit the customer’s needs and the application. The label reliably indicates any unauthorized opening of the housing and thus potential tampering attempts. During scheduled servicing it is important for the shop to see if the most recent maintenance was expertly performed and that the belt has not been tampered with since then. A label from Schreiner ProTech modified to suit the customer’s needs and the application guarantees this. Special die cuts will destroy the label in an attempt to remove it and indicate any unauthorized opening of the housing, thus protecting the manufacturer and bike retailers against unjustified warranty claims. The development posed the challenge of modifying a basic label for permanent adhesion to the powder-coated surface of the drive housing and destruction in a peel-off attempt. The font and color of the label match Brose Antriebstechnik’s corporate design. “Together with Schreiner ProTech we developed a label that fully meets the requirements for our premium e-bike drives in terms of high-grade appeal, quality and technical design,” says Holger Pries, Head of Development Brose Antriebstechnik. The label optimally ensures and documents that the drive has exclusively been serviced in a professional manner or is in original condition. For more information, please contact: Eva Manzenreiter, Product Communication Phone +49 89 31584-5517, eva.manzenreiter@schreiner-group.com

As the new and preferred sales partner for Varcotec's innovative Lock 3 technology, Siegwerk is expanding its range of packaging inks and varnishes with a unique antimicrobial dispersion varnish suitable for a wide range of applications and packaging types. Siegburg, 16. June 2020. – Siegwerk, one of the leading suppliers of printing inks for packaging applications and labels, and Varcotec, a specialist for technically sophisticated overprint varnishes made for the printing industry, have entered into a distribution partnership for Varcotec's Lock 3 antimicrobial coating technology in the EMEA region (Europe, Middle East and Africa). This innovative dispersion varnish is the first of its kind, and was developed in cooperation with a spin-off company affiliated with the University of Regensburg, Germany. The antimicrobial effectiveness of this product has already been confirmed by several independent testing institutions. “With the integration of Varcotec's innovative product technology, we are adding a unique solution for various applications and packaging industries to our portfolio, thereby once again reinforcing the holistic nature of our offers for the packaging market,” said Hanns Martin Kaiser, Vice President Paper & Board EMEA and Liquid Food Packaging at Siegwerk. Even if printed surfaces on packaging generally do not constitute a hazard, consumers continue to be exposed to potentially contaminated surfaces. As different germs (e.g. viruses, bacteria, fungi) exhibit varying survival times, the Lock 3 technology makes a valuable contribution to avoid risks of transmitting bacterial and viral infections when products’ printed surfaces (outer packaging, partitions, exercise books, etc.) are handled by multiple people in short time. Lock 3 antimicrobial solutions help to provide extra security in a multitude of applications by interrupting chains of infection early on. “With Lock 3, Varcotec has launched the first antimicrobial dispersion varnish based on the principle of photodynamics in order to reliably reduce the germ loads,” added Paul Pain, Global Head of Water-based Technology at Siegwerk. “We are pleased to be able to include this unique product innovation in our portfolio, allowing us to offer this to our customers as partner of Varcotec." According to scientific data, germs can survive on surfaces from a few hours up to several months. “Until now, it has not been possible to apply a reliable coating onto absorbent substances, such as paper and cardboard, which would continuously and permanently destroy those germs,” explains Joachim Frings, from Sales and Development at Varcotec. “With Lock 3 we have succeeded in developing a varnish system which can demonstrably reduce the germ load on a wide range of printed products, already at ambient lighting conditions.” The water-based overprint varnish Lock 3 allows for permanent, independent disinfection of the printed surfaces under ambient room lighting or in open daylight. Lock 3 contains a specially patented substance, taking advantage of the principle of photodynamics: the photocatalyst is activated by visible light and transfers the energy thus absorbing the surrounding oxygen. This process creates so-called singlet oxygen, efficiently killing germs by oxidizing their shells. For more than 20 years, singlet oxygen has been used routinely in medicine for the treatment of tumors and degenerative diseases. Antimicrobial use of singlet oxygen was confirmed during this time period. No resistance develops against singlet oxygen, in contrast to what is usually observed with antibiotics and conventional biocides. The active oxygen is gaseous: It can easily reach and kill microorganisms on dry and damp surfaces. With a range of about 1 mm it reaches far enough to destroy surface microorganisms, but remains constrained from arbitrary release into the environment. The effectiveness of this varnish was already validated by several independent testing institutions. Tests have shown that Lock 3 varnishes can kill both bacteria (according to ISO 22196 (mod.) for paper and cardboard) and infectious viral particulates (based on ISO 21702 (mod.)) by more than 99%. Additional tests against other virus strains, including three members of the Coronavirus family, are currently in the testing phase. Lock 3 can already be applied to paper and cardboard by means of all commonly used printing machinery and coating equipment. The first pilot applications on plastic films are already underway, an expansion of the application range is under development and subjected to the required testing. This varnish is currently the only fully effective antimicrobial technology on the market which functions independent of moisture and temperature conditions and remains effective on dry surfaces. The photodynamic effect is temporarily suspended in darkness, but reactivated immediately upon renewed exposure to light. This varnish remains effective for up to three years. In contrast, other comparable technologies, such as coatings containing silver and copper, require the presence of moisture or even UV radiation to obtain a sufficient effectiveness for disinfection. Lock 3 dispersion varnishes are free from heavy metals, odorless and without impact on the recycling process of respective products or packaging. “We are very pleased to have gained a leading player in the printing ink and packaging industry such as Siegwerk as our partner, able to integrate our unique and innovative coating technology into a significantly larger and international sales structure, in order to increase the product’s market exposure,” added Jens Frings, Managing Director of Varcotec. Within the framework of this partnership, Siegwerk will commence marketing Varcotec's Lock 3 products in the EMEA region starting in June 2020. These products will first be available in Germany, then gradually launched in Central Europe with all countries in EMEA serviced by end of this year. The production of these varnish coating systems is still the responsibility of Varcotec. In the beginning, the product portfolio will only consist of water-based solutions. At the same time, the partners remain open to advancement of joint development activities in other areas of application, coating technologies and market regions at a later date. About Siegwerk Siegwerk, a family company in its sixth generation, is one of the world’s leading manufacturers of printing inks and individual solutions for packaging, labels and catalogs. With more than 180 years of experience, the company has in- depth knowledge and expertise of many printing processes. A global production and service provider network provides customers with products and services of consistently high quality. True to the company philosophy of “Ink, Heart & Soul,” Siegwerk strives for a long-term cooperation with its business partners. Siegwerk employs around 5,000 people worldwide in more than 30 foreign subsidiaries and is headquartered in Siegburg, near Cologne. You can find more information on Siegwerk at www.siegwerk.com About Varcotec Varcotec GmbH is a specialist in the development and manufacture of ecologically high-quality and economically efficient system solutions for the printing industry. The company's future-oriented product range includes innovative and technologically sophisticated varnish coatings of the dispersion, oil pressure, HUV, LE, LED, and conventional UV type, tailor-made for the individual needs of each of its customers. Varcotec believes the use of energy-saving and emissions-reducing materials in the printing process must be a priority in research and product development at the company. When developing new products, the company also works closely with independent testing institutions, thereby enabling achievement of the highest quality standards. Further information on Varcotec can be found at www.varcotec.de Media contact: Siegwerk: Dr. Bettina Horenburg Director Corporate Communications Tel.: +49 2241 304-732 Email: bettina.horenburg@siegwerk.com

Company inaugurates segregated 7,000-sq-ft space with a new back-number system and its third 100% inspection platform. Lakewood, NJ – Luminer, a labeling solutions provider specializing in extended content labels (ECLs) for pharmaceutical ethical and OTC packaging, clinical trials and various other narrow web applications for the cosmetics, F&B and chemicals sectors, has streamlined its precision product inspection capabilities by introducing a dedicated 7,000-square-foot inspection suite at its primary manufacturing facility in Lakewood, NJ. The quality management segregation also comes with an infrastructure investment: the company has added its third 100% inspection platform, as well as a back-number validation system. The dedicated space will further improve Luminer’s comprehensive quality management processes. In particular, it is designed to optimize QA/QC oversight for the company’s specialty, extended content labels. Due to their inherently stacked, page-over-page nature, ECLs pose unique inspection challenges requiring niche-specific solutions. Luminer provides 100% label inspection – a must for its broad set of pharma customers. For ECLs, this entails a complex process that involves, among other extra steps, precision vision systems inspecting individual sheets prior to folding, glue line monitoring to ensure all ECL pages are affixed properly and in correct order, and final inspection initiatives such as thickness monitoring to confirm label-on-label mounting veracity. Luminer’s addition of a back-number validation system provides additional assurance for pharma customers, by helping to ensure labels are matched to their proper individual packages. Among other benefits, this helps simplify the label application process and, for prescription products, lends to easier compliance with unit-level serialization requirements. “The new inspection suite helps reinforce Luminer as a medium-sized label manufacturer with big-shop production and quality control capabilities,” said Tom Spina, President & CEO of Luminer. “Extended content labels especially demand a thorough, multi-step inspection process. The dedicated quality management space and new infrastructure will further streamline our workflow, expediting turnaround time from initial quote to production to delivery.” Luminer recently incorporated a new extended content label production line, a seven-figure investment that doubled its ECL manufacturing capacity. The new line’s exemplary production speeds foster both efficiency and cost-effectiveness, ROIs that Luminer will be able to pass on to customers. # # # About Luminer Since 1989, Luminer has specialized in combining adhesive coating technology with narrow web flexographic printing and converting expertise. The company is a leader in several industry niches, chief among them extended content labels (ECLs) for clinical trial and other pharmaceutical applications. In addition, Luminer is a prominent provider of on-pack/in-pack promotional products, cosmetic and fragrance sampling devices and pressure-sensitive adhesive coated products. The company also serves the food & beverage and chemicals sector with a wide variety of labeling solutions. Located in Lakewood, NJ and Red Lion, PA, Luminer’s two facilities are each ISO 9001:2015 certified, operate under cGMP guidelines, and regularly undergo audits from high-profile pharmaceutical, cosmetics and health & beauty aid clients. For more information, call (732) 365-3673 or visit www.luminer.com. client: Luminer contact: Christopher Dale Turchette Agency (973) 227-8080, ext. 116 cdale@turchette.com Dan Goldstein Luminer (732) 886-6557, ext. 114 dgoldstein@luminer.com

At its virtual meeting on 11 June, the Management Board was updated on how EMA is prioritising the response to the COVID-19 pandemic and what measures the Agency has put in place to tackle the crisis. The Agency and the European medicines regulatory network are currently operating under a network COVID-19 business continuity plan to ensure that core public and animal health regulatory activities, such as the authorisation, maintenance and supervision of medicines continue to be carried out during the pandemic and do not incur any possible delays. In particular, the network is mobilised to support the development and evaluation of medicines for COVID-19. The Board noted that EMA is working on providing an increased level of transparency for medicines and vaccines targeting COVID-19, including the publication of clinical data for these products. More information will be communicated shortly. In order to speed up the assessment of promising investigational medicines during the pandemic, EMA’s human medicines committee (CHMP) reviews data as they become available on a rolling basis, while development is still ongoing. The Board agreed to the introduction of a new fee for the ‘rolling review’ assessment for potential marketing authorisations. This fee would be deducted from the fee that would become due with the submission of an actual marketing authorisation application. Small and medium-sized enterprises (SMEs) are eligible for a 90% reduction. Revised implementing rules to the Fee Regulation will be published shorty. Positive assessment of EMA operations in 2019 The Board has assessed and adopted the Executive Director’s annual activity report for 2019. The Board noted that although business continuity planning for Brexit and the Agency’s relocation to the Netherlands had taken up considerable resources last year, EMA managed to maintain its core operations and delivered its 2019 work programme. The UK portfolio of medicines had been reallocated to other EU Member States and the Board was confident that all steps have now been taken to ensure that the network is prepared for any scenario at the end of the transition period of the UK’s withdrawal from the EU. Other achievements highlighted by the Board include the Agency’s activities in the global fight against antimicrobial resistance and the implementation by the EU and the USA of the mutual recognition agreement for inspections of manufacturing sites for certain human medicines in their respective territories. The Board acknowledged the progress made in developing the Regulatory Science Strategy to 2025. This strategy will be an important element of the next joint EMA/HMA European Medicines Agencies Network Strategy to 2025 due to be released for public consultation next month. It also received an update on the work to ‘future proof’ EMA, which has strengthened the Agency’s ability to perform new activities with the EU network and tackle new challenges such as big data, digitalisation, new scientific methods and technologies. The annual activity report describes the implementation of the Agency’s work programme and the management and control systems in place. Every year it is submitted to the Board, which assesses whether the Agency has carried out its activities in accordance with the principles of good governance. The report, as well as the assessment by the Board, will be published on the EMA website shortly. EMA 2018-2019 annual reports on independence The Board adopted a plan for implementing the recommendations set out in the 2018-2019 annual reports on independence, which were endorsed by the Board at its March 2020 meeting. The recommendations will be implemented in steps, with several actions to be carried out in 2020, including changes to EMA’s policy relating to the handling of competing interests of scientific committees’ members and experts. The revision takes into account the requirement for members and alternates of EMA’s Committee for Advanced Therapies (CAT) to declare interests in the biotechnology and medical device sectors which could affect their impartiality, as well as the requirement for experts to declare interests in relation to their personal or organisation’s involvement in the repurposing of a medicine. The changes introduced also include a minor update to the definition of financial interest, the definition of partner, additional restrictions for inspectors declaring close family interests and grants/funding, as well as reference to the new EU General Data Protection Regulation (GDPR). The revised policy will come into effect in January 2021. EMA’s policies for Management Board members and staff have been aligned and the declaration of interests form for experts will be updated accordingly. The revisions demonstrate the Agency’s commitment to a policy that effectively addresses the Agency’s specific needs regarding independence. The 2018-2019 annual reports on independence, together with the revised policies, will be published shortly. Development of the Clinical Trials Information System (CTIS) for the EU Clinical Trials Regulation The Board endorsed the methodology and next steps to further develop the Clinical Trials Information System (CTIS) ‘go-live’ plan. A group will be responsible for prioritising all outstanding issues to the CTIS governance and matching the items remaining after the audit to the capacity available before go-live and thereafter. This group will include representatives of the Member States product owners, sponsors product owners, as well as representatives from EMA and the European Commission. For the purpose of the prioritisation exercise, as a working assumption, it is proposed to fix the go-live date of CTIS to December 2021. The Board noted that further operational assessments of various elements of CTIS were carried out in May, including the public portal and the publication of documents. This allows finalisation of the scope of the audit version of the system. The Board also noted the progress in the development of CTIS made by the supplier. In view of the upcoming start of the audit in December 2020, a key milestone for CTIS, the Board decided to extend the monitoring of agreed key performance indicators until after the CTIS audit and to monitor the delivery of the items selected for audit and go-live. Date for election of new EMA Executive Director The Management Board will elect a new Executive Director in a virtual meeting on Thursday, 25 June 2020. Contact point EMA press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

Berlin, 12 June 2020 – European Bioplastics, the association, representing the bioplastics industry in Europe, is pleased to announce the appointment of Joanna Dupont-Inglis as new Head of European Public Affairs. She assumed her position on 1 June 2020 and will be based in Brussels. Bioplastics play a crucial role in helping to achieve the European Green Deal. The deal includes the European Union’s transition to a real resource-efficient economy with zero-net-green-house-gas-emissions by 2050. “I’m delighted to take up the position as Head of EU Affairs at European Bioplastics. Being the first contact point for decision makers and other relevant political stakeholders in Brussels, I’m looking forward to highlighting the important contributions that bioplastics make towards achieving the EU’s ambitious Green agenda”, says Dupont-Inglis. “With her broad experience in the bioeconomy, we are very happy to have Joanna on board. EUBP has been working together with Joanna for many years. Besides her outstanding technical and political expertise, we also know her for being a strong team player with a remarkable social competence”, says François de Bie, Chairman of EUBP. “This year can be considered of key importance for the bioplastics industry and Joanna entered at just the right time”, he adds. Prior to joining European Bioplastics (EUBP), Joanna Dupont-Inglis held several senior positions at EuropaBio over a period of 10 years, including the Director for Industrial Biotechnology, Deputy Secretary General and Secretary General as of 2018. Joanna also chaired the European Bioeconomy Stakeholder’s Panel throughout the course of its four-year mandate and served for several years as a board member for Suschem, the Sustainable Chemistry Platform Before her work at EuropaBio, Joanna Dupont-Inglis gathered comprehensive experience in the Brussels policy arena by working for the European Commission’s DG Environment and for two renowned Brussels-based public affairs consultancies. She holds a degree in Environmental Science and European Studies from the University of Sussex and is a board member of the Women in Life Sciences Network. European Bioplastics (EUBP) is the European association representing the interests of the bioplastics industry along the entire value chain. Its members produce, refine, and distribute bio plastics i.e. plastics that are bio-based, biodegradable, or both. More information is available at www.european-bioplastics.org. Press contact: Oliver Buchholz, Communications Manager, European Bioplastics, Marienstr. 19/20, 10117 Berlin, phone: +49 (0) 30 28482 353, fax: +49 (0)30 284 82 359, email: press@european-bioplastics.org

Orion Znakowanie Towarow Adds Evolution Series Orion Znakowanie Towarow, a print service provider in Wroclaw, Poland, has served a number of customers within the fast-moving consumer goods (FMCG) market for over twenty years. Specializing in label production, Orion was one of the first Polish companies to implement Mark Andy’s newest Evolution Series flexo press following its debut at the 2019 Labelexpo trade show in Brussels. “We continue our successful co-operation with Mark Andy,” commented Marek Dziewanowski, President of Orion Znakowanie Towarow. “It’s the third press from this American vendor purchased by our company during the last four years. The investment is another natural step of modernization of our equipment. Evolution Series replaced the long-serving device from another vendor and significantly increased our potential in terms of label production to include more advanced and complex finishes.” Orion’s production also increased as a result of the added ability to print multi-color labels on different substrates. The Evolution Series press handles web of 440 mm width and offers speed up to 230 m/min. It comes standard equipped with: unwind/rewind, 8 flexo stations (based on servo technology) with chilled impression cylinders, preregister & auto register, VariPrint system, web reversal system, Corona unit, cold foil stamping, laminator, UV curing system, two die-cutters (incl. QCDC) and web inspection camera. The press also offers a function for peel-off labeling production. “The Evolution Series is based on a printing platform known from Performance Series P7, that we have used since 2017; it is a significant support for that press as well,” Marek Dziewanowski said. “Due to their compatibility, we may do the same jobs in both presses or use them alternatively.” In addition to the most recent installation of Evolution Series press and the Performance Series P7, Orion’s facility also includes a Digital Series HD which was purchased mid last year. The Digital Series HD allows for efficient production of smaller runs of highly finished labels. Marek Dziewanowski confirms that the device met all his expectations: “Due to our investments, we have an appropriate balance in coverage with all three Mark Andy presses on our production schedule. Digital Series HD works in a three-shift system and is highly loaded, especially in the current, more difficult market situation. We are very conscious that pandemic hit our customers from different industries, but also hit end consumers as well. Our business became more flexible after investing in both conventional and digital technologies, which became our strong advantage and let us proceed with the planned investment in Evolution Series press with assurance.” “Despite the ongoing restrictions and limitations that are set in place as a result of COVID-19 pandemic, we also try to fulfill the deadlines for our product deliveries. However, all of our actions consider the procedures and protocols set forth by law or the internal rules of a printing house,” added Lukasz Chruslinski, Sales Manager, Mark Andy Poland. “Both parties were incredibly satisfied that the delivery, installation, and start-up of the press went smoothly and was completed according to schedule.” Przemyslaw Polkowski, Director Mark Andy Poland, concludes: “Implementation at Orion Znakowanie Towarow is another successfully finalized agreement with the Polish customer, proceeded in this difficult time. Therefore, we deeply thank Mr. Marek Dziewanowski for his trust to Mark Andy as a vendor of the press, but also as a strategic partner in his investment schedule and production run by his company. We are conscious of our responsibility when we think about three Mark Andy presses that decide about efficient and timely label production in which Orion is specialized. We also hope that the Evolution Press, which follows P7 and Digital Series HD, will be another significant strengthening of Orion’s equipment park.” About Mark Andy Inc. Mark Andy Inc. is the Total Solutions Partner to the label and packaging industry with a mission to be 'the supplier of choice with high quality innovative solutions that drive customer profitability.' The company responds to business needs by offering a broad range of equipment, education, support, and supplies to printers and converters around the world. Partnering with Mark Andy means access to award-winning technologies including Mark Andy flexographic and digital printing presses, Rotoflex offline finishing systems, and a complete line of consumables and press room supplies from Mark Andy Print Products. The company has the largest customer support team with global coverage, offering spare parts, technical service, retrofits and rebuilds, PM programs, and superior training through Mark Andy University. Mark Andy is headquartered in St. Louis, Missouri, USA, with sales and distribution offices worldwide. For additional media information, please contact Danna Schwerdt at danna.schwerdt@markandy.com +1 636 357 7799 www.markandy.com | www.rotoflex.com

B&R presents new ACOPOSinverter series for three-phase synchronous and induction motors The ACOPOSinverter P86 is a series of frequency inverters for three-phase synchronous and induction motors, with or without encoders. It covers a wide power spectrum from 0.75 to 75 kW and is particularly well-suited for packaging, conveyor system, material processing and hoisting gear applications. B&R's P86-series inverters already comply with the IE efficiency factors standardized in EN 61800-9-2. The future-proof inverters are easy to configure and exceptionally flexible. The new ACOPOSinverter series is also equipped with the dual-channel safety function Safe Torque Off (STO) in accordance with SIL3 / PLe. Powerful dynamics and scalability The frequency inverters are particularly well suited for dynamic applications. They can deliver up to 220% of the nominal output torque for two seconds. They can be used for open-loop or closed-loop control of induction motors (IE2, IE3), synchronous motors and reluctance motors. An integrated POWERLINK interface, numerous I/O channels, and embedded encoder and optional interface cards offer maximum flexibility in plant design. Rugged design for years of duty The ACOPOSinverter P86 series has an exceptionally rugged design, and is built to perform under harsh conditions. They easily cope with vibrations, shock, dust and temperatures up to 60°C while maintaining consistent performance. Extensive portfolio The new P86 series further expands B&R's ACOPOSinverter portfolio. Together with the P66, P76 and P96 series, they cover a range of drive technology profiles for three-phase induction motors and synchronous motors with a voltage supply from 200 to 600 V and a power rating from 0.18 to 200 kW. With easily scalable functionality and full integration into the B&R automation landscape, the ACOPOSinverter family is suited for a wide range of applications, from small machine modules to complex plants. About B&R B&R is an innovative automation company with headquarters in Austria and offices all around the world. On July 6, 2017, B&R became a business unit of the ABB Group. As a global leader in industrial automation, B&R combines state-of-the-art technology with advanced engineering to provide customers in virtually every industry with complete solutions for machine and factory automation, motion control, HMI and integrated safety technology. With Industrial IoT communication standards like OPC UA, POWERLINK and openSAFETY as well as the powerful Automation Studio software development environment, B&R is constantly redefining the future of automation engineering. The innovative spirit that keeps B&R at the forefront of industrial automation is driven by a commitment to simplifying processes and exceeding customer expectations. For more information, visit www.br-automation.com. Press‌ ‌contact:‌ ‌ Corporate‌ ‌Communications‌ ‌ t‌ ‌+43‌ ‌7748‌ ‌6586-0‌ ‌ press@br-automation.com‌ ‌ B&R‌ ‌Industrial‌ ‌Automation‌ ‌ B&R‌ ‌Strasse‌ ‌1,‌ ‌5142‌ ‌Eggelsberg,‌ ‌Austria‌